Browse C3AR1

Summary
SymbolC3AR1
Namecomplement component 3a receptor 1
Aliases C3AR; AZ3B; HNFAG09; C3a-R; complement component 3 receptor 1; C3a anaphylatoxin chemotactic receptor
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein.
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

Receptor for the chemotactic and inflammatory peptide anaphylatoxin C3a. This receptor stimulates chemotaxis, granule enzyme release and superoxide anion production.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001819 positive regulation of cytokine production
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002430 complement receptor mediated signaling pathway
GO:0002526 acute inflammatory response
GO:0002673 regulation of acute inflammatory response
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0002697 regulation of immune effector process
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0002920 regulation of humoral immune response
GO:0003013 circulatory system process
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006956 complement activation
GO:0006959 humoral immune response
GO:0007200 phospholipase C-activating G-protein coupled receptor signaling pathway
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0008015 blood circulation
GO:0010573 vascular endothelial growth factor production
GO:0010574 regulation of vascular endothelial growth factor production
GO:0010575 positive regulation of vascular endothelial growth factor production
GO:0010758 regulation of macrophage chemotaxis
GO:0010759 positive regulation of macrophage chemotaxis
GO:0016485 protein processing
GO:0030335 positive regulation of cell migration
GO:0030449 regulation of complement activation
GO:0030593 neutrophil chemotaxis
GO:0030595 leukocyte chemotaxis
GO:0032103 positive regulation of response to external stimulus
GO:0040017 positive regulation of locomotion
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0048246 macrophage chemotaxis
GO:0048514 blood vessel morphogenesis
GO:0050727 regulation of inflammatory response
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051272 positive regulation of cellular component movement
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0051604 protein maturation
GO:0055074 calcium ion homeostasis
GO:0060326 cell chemotaxis
GO:0070613 regulation of protein processing
GO:0071621 granulocyte chemotaxis
GO:0071622 regulation of granulocyte chemotaxis
GO:0071624 positive regulation of granulocyte chemotaxis
GO:0071674 mononuclear cell migration
GO:0071675 regulation of mononuclear cell migration
GO:0072376 protein activation cascade
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0090022 regulation of neutrophil chemotaxis
GO:0090023 positive regulation of neutrophil chemotaxis
GO:0097529 myeloid leukocyte migration
GO:0097530 granulocyte migration
GO:1901342 regulation of vasculature development
GO:1902622 regulation of neutrophil migration
GO:1902624 positive regulation of neutrophil migration
GO:1903317 regulation of protein maturation
GO:1904018 positive regulation of vasculature development
GO:1990266 neutrophil migration
GO:2000147 positive regulation of cell motility
GO:2000257 regulation of protein activation cascade
Molecular Function GO:0004875 complement receptor activity
GO:0004876 complement component C3a receptor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04080 Neuroactive ligand-receptor interaction
hsa04610 Complement and coagulation cascades
Reactome R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-166658: Complement cascade
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6798695: Neutrophil degranulation
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-977606: Regulation of Complement cascade
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolC3AR1
Namecomplement component 3a receptor 1
Aliases C3AR; AZ3B; HNFAG09; C3a-R; complement component 3 receptor 1; C3a anaphylatoxin chemotactic receptor
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between C3AR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between C3AR1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27297552Melanoma; Lung carcinoma; Breast carcinoma; liver carcinomaInhibit immunityHowever, CD8(+) TILs do not routinely express IL10, as autocrine complement C3 inhibits IL10 production through complement receptors C3aR and C5aR.
Summary
SymbolC3AR1
Namecomplement component 3a receptor 1
Aliases C3AR; AZ3B; HNFAG09; C3a-R; complement component 3 receptor 1; C3a anaphylatoxin chemotactic receptor
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of C3AR1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -1.90; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolC3AR1
Namecomplement component 3a receptor 1
Aliases C3AR; AZ3B; HNFAG09; C3a-R; complement component 3 receptor 1; C3a anaphylatoxin chemotactic receptor
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of C3AR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4610.228
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4680.791
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4560.731
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0370.941
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6010.658
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8480.635
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0760.879
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.240.866
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1580.923
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.3260.381
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.6250.506
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0850.648
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of C3AR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolC3AR1
Namecomplement component 3a receptor 1
Aliases C3AR; AZ3B; HNFAG09; C3a-R; complement component 3 receptor 1; C3a anaphylatoxin chemotactic receptor
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of C3AR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolC3AR1
Namecomplement component 3a receptor 1
Aliases C3AR; AZ3B; HNFAG09; C3a-R; complement component 3 receptor 1; C3a anaphylatoxin chemotactic receptor
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of C3AR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by C3AR1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolC3AR1
Namecomplement component 3a receptor 1
Aliases C3AR; AZ3B; HNFAG09; C3a-R; complement component 3 receptor 1; C3a anaphylatoxin chemotactic receptor
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of C3AR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolC3AR1
Namecomplement component 3a receptor 1
Aliases C3AR; AZ3B; HNFAG09; C3a-R; complement component 3 receptor 1; C3a anaphylatoxin chemotactic receptor
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of C3AR1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolC3AR1
Namecomplement component 3a receptor 1
Aliases C3AR; AZ3B; HNFAG09; C3a-R; complement component 3 receptor 1; C3a anaphylatoxin chemotactic receptor
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between C3AR1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolC3AR1
Namecomplement component 3a receptor 1
Aliases C3AR; AZ3B; HNFAG09; C3a-R; complement component 3 receptor 1; C3a anaphylatoxin chemotactic receptor
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting C3AR1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.